Fimasartan Ameliorates Nonalcoholic Fatty Liver Disease through PPARδ Regulation in Hyperlipidemic and Hypertensive Conditions
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Fimasartan Ameliorates Nonalcoholic Fatty Liver Disease through PPARδ Regulation in Hyperlipidemic and Hypertensive Conditions
Authors
Keywords
-
Journal
PPAR Research
Volume 2017, Issue -, Pages 1-14
Publisher
Hindawi Limited
Online
2017-03-14
DOI
10.1155/2017/8048720
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Serum aminotransferases in nonalcoholic fatty liver disease are a signature of liver metabolic perturbations at the amino acid and Krebs cycle level1,2
- (2016) Silvia Sookoian et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- Noninvasive fatty liver markers predict liver disease mortality in the U.S. population
- (2016) Aynur Unalp-Arida et al. HEPATOLOGY
- Pathophysiology of Non Alcoholic Fatty Liver Disease
- (2016) Salvatore Petta et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Effects of aerobic exercise on the resting heart rate, physical fitness, and arterial stiffness of female patients with metabolic syndrome
- (2016) Seol-Jung Kang et al. Journal of Physical Therapy Science
- AMPK: A cellular metabolic and redox sensor. A minireview
- (2014) Najeeb Shirwany Frontiers in Bioscience-Landmark
- Influence of Hepatic Dysfunction on the Pharmacokinetics and Safety of Fimasartan
- (2013) Choon Ok Kim et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Berberine metabolites exhibit triglyceride-lowering effects via activation of AMP-activated protein kinase in Hep G2 cells
- (2013) Shijie Cao et al. JOURNAL OF ETHNOPHARMACOLOGY
- The effects of running exercise on oxidative capacity and PGC-1α mRNA levels in the soleus muscle of rats with metabolic syndrome
- (2012) Fumiko Nagatomo et al. Journal of Physiological Sciences
- AMPK activation, a preventive therapeutic target in the transition from cardiac injury to heart failure
- (2011) C. Beauloye et al. CARDIOVASCULAR RESEARCH
- Effect of age on the pharmacokinetics of fimasartan (BR-A-657)
- (2011) Hae Won Lee et al. Expert Opinion on Drug Metabolism & Toxicology
- Secondary causes of nonalcoholic fatty liver disease
- (2011) Jacob M. Kneeman et al. Therapeutic Advances in Gastroenterology
- Globular adiponectin regulates energy homeostasis through AMP-activated protein kinase–acetyl-CoA carboxylase (AMPK/ACC) pathway in the hypothalamus
- (2010) Jun-Ping Wen et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue
- (2009) Hiroshi Kudo et al. LIVER INTERNATIONAL
- AMPK and PPARδ Agonists Are Exercise Mimetics
- (2008) Vihang A. Narkar et al. CELL
- The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice
- (2008) Wei-Na Cong et al. LIFE SCIENCES
- Nonalcoholic fatty liver disease and mitochondrial dysfunction
- (2008) Yongzhong Wei et al. WORLD JOURNAL OF GASTROENTEROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started